肝脏 ›› 2020, Vol. 25 ›› Issue (11): 1181-1184.

• 肝癌 • 上一篇    下一篇

索拉非尼对肝癌细胞增殖凋亡及JAK-STAT信号通路的影响

程秀莲, 韩利峰, 唐秀丽, 赵娜, 刘宁宁   

  1. 075000 河北 张家口市第一医院消化科
  • 收稿日期:2019-08-01 出版日期:2020-11-30 发布日期:2020-12-22
  • 基金资助:
    河北省医学科学研究课题项目(20191717)

Effects of sorafenib on proliferation and apoptosis of hepatocellular carcinoma cells and JAK-STAT signaling pathway

CHENG Xiu-lian, HAN Li-feng, TANG Xiu-li, ZHAO Na, LIU Ning-ning   

  1. Department of Gastroenterology,Zhangjiakou First Hospital,Hebei 075000,China
  • Received:2019-08-01 Online:2020-11-30 Published:2020-12-22

摘要: 目的 探讨索拉非尼对肝癌细胞株HepG2、MHCC97-H、QGY- 7701、Bel-7404和SKHep-1细胞活性和细胞凋亡的影响,以及对JAK-STAT信号通路的影响。方法 利用溴化噻唑蓝四氮唑(MTT)比色法和流式细胞仪分别检测了不同浓度索拉非尼对各细胞株抑制作用以及细胞凋亡的影响;采用qRT-PCR法和免疫印迹法分别检测了索拉非尼在不同人肝癌细胞株中对JAK-STAT信号通路中JAK2和STAT3 mRNA和蛋白表达量的影响。结果 MTT结果显示,索拉非尼对肝癌HepG2、MHCC97-H、QGY- 7701、Bel-7404和SKHep-1细胞株半数抑制浓度分别为(13.17±0.09)μmol/L、(9.28±0.05)μmol/L、(11.97±0.07)μmol/L、(8.49±0.06)μmol/L和(10.54±0.03)μmol/L;当索拉非尼浓度为20 μmol/L,孵育细胞时间为72 h时,其抑制效果最佳;与对照组相比,索拉非尼均能促进肝癌HepG2、MHCC97-H、QGY- 7701、Bel-7404和SKHep-1细胞株的凋亡(P< 0.01);索拉非尼能够降低肝癌细胞株JAK2和STAT3 mRNA和蛋白的表达量。结论 索拉非尼能够抑制肝癌细胞的活性,诱导细胞发生凋亡;JAK-STAT信号通路普遍存在于各肿瘤细胞中,索拉非尼能够抑制信号通路蛋白表达,提示索拉非尼作用靶点可能是JAK-STAT信号通路,也可能是防治其他肿瘤的新靶点。

关键词: 肝癌细胞, 流式细胞仪, MTT法, qRT-PCR, 免疫印迹法, JAK2蛋白, STAT3蛋白

Abstract: Objective To investigate the effects of sorafenib on the activity and apoptosis of hepatoma cell lines (HepG2,MHCC97-H,QGY-7701,Bel-7404 and SKHep-1) and tyrosine kinase Janus kinase and transducer and activator of transcription (JAK-STAT) signaling pathway.Methods The effects of different concentrations of sorafenib on the inhibition and apoptosis of various cell lines were detected by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry.The messenger RNA (mRNA) and protein expression of tyrosine kinase Janus kinase 2 (JAK2) and transducer and activator of transcription 3 (STAT3) in JAK-STAT signaling pathway were detected by quantitative real time polymerase chain reaction and western blot,respectively.Results MTT showed that the half maximal inhibitory concentrations of sorafenib for HepG2,MHCC97-H,QGY-7701,Bel-7404 and SKHep-1 cell lines were (13.17±0.09) μmol/L,(9.28±0.05) μmol/L,(11.97±0.07) μmol/L,(8.49±0.06) μmol/L and (10.54±0.03) μmol/L,respectively.When the concentration of sorafenib was 20 μmol/L and the incubation time was 72 h,the inhibitory effect was the best.Compared with the control group,sorafenib could promote the cell apoptosis,as well as reduce the mRNA and protein expression of JAK2 and STAT3 in liver cancer cell lines (P<0.01).Conclusion Sorafenib can suppress the activity of liver cancer cells,induce apoptosis of cells,and inhibit the protein expression of JAK-STAT signaling pathway in tumor cells.It is suggested that JAK-STAT signaling pathway may be the target of sorafenib,and the potential target for prevention and treatment of other tumors.

Key words: Hepatocellular carcinoma cell, Flow cytometry, MTT assay, Quantitative real time polymerase chain reaction, Western blot, Tyrosine kinase Janus kinase 2 protein, Transducer and activator of transcription 3 protein